ArticleStem cell research & therapy2026
Identifying NOTCH signaling-specialized hematopoietic supportive subpopulation from mesenchymal stem cells.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman umbilical cord mesenchymal stem cells (UC-MSCs) are widely studied as a promising cellular therapy for a variety of diseases due to their accessible sources, less of ethical concerns, and capacities for immunomodulation and tissue repair. However, cellular heterogeneity arising during in vitro expansion imposes challenges in quality control for clinical applications and transform, requiring further investigation.
methodsTwo fetal umbilical cords were obtained from Sinogene C&G Stem Cells Co., Ltd. Primary UC-MSCs were isolated and subjected to continuous in vitro passaging culture. The harvested cells were sorted for single-cell RNA sequencing. A total of 78,178 cells and 14 subpopulations were screened for downstream bioinformatic analysis. Experimental validation was performed through both in vitro cell assays and in vivo animal studies.
resultMid-passage UC-MSCs showed more favorable functional performance, based on differential gene expression and functional enrichment analysis. Furthermore, we obtained an optimal subpopulation (C8) during clinical-grade cell culture by holistic evaluation of stemness, hematopoietic support capacity, and immunomodulatory potential. The stemness maintenance of C8 subpopulation was closely associated with NOTCH signaling pathway, as identified by cell-cell communication network analysis. Further analyses established NOTCH2 as the dominant receptor mediating NOTCH signaling in UC-MSCs. Notably, we identified MLPH and LPXN as signature markers specifically enriched in the C8 subpopulation. MLPH
conclusionsMid-passage UC-MSCs demonstrate favorable characteristics for clinical applications. The UC-MSC subpopulation with high NOTCH signaling activity exhibits enhanced hematopoietic support and immunosuppressive capabilities. MLPH and LPXN serve as ideal markers for isolating this functionally subpopulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.